Gamida Cell (Nasdaq: GMDA), is developing a diverse cell therapy pipeline of potentially curative candidates for patients with solid tumor, blood cancers and other serious blood diseases.

The company’s broad proprietary NAM (nicotinamide) expansion technology is used to augment allogeneic cell sources including umbilical cord blood-derived cells and NK cells to create therapy candidates with potential to redefine standards of care.

Omidubicel, Gamida Cell’s lead product is a first-in-class NAM-enabled stem cell therapy candidate developed as a potential life-saving allogeneic hematopoietic stem cell (bone marrow) transplant for patients with blood cancers. Omidubicel received breakthrough and orphan drug designations in the US and EU.  The company submitted to the FDA the Biologics License Application (BLA) for omidubicel and was granted Priority Review with a PDUFA target action date set for January 30, 2023.

Gamida cell applies the capabilities of its NAM technology to develop a pipeline of readily available cell therapy candidate for the treatment of hematologic and solid tumors.  GDA-201, Gamida Cell’s NK cell immunotherapy candidate is in Phase 1/2 clinical study for the treatment of follicular and diffuse large B cell lymphomas.